Codexis, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA 2026 at the Hynes Convention Center in Boston. Through presentations and a panel discussion, the Company highlighted how its ECO Synthesis® Manufacturing Platform is advancing the production of siRNA, now enabling stereochemical control while add
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
A week ago, Codexis, Inc. ( NASDAQ:CDXS ) came out with a strong set of first-quarter numbers that could potentially...
A week ago, Codexis, Inc. ( NASDAQ:CDXS ) came out with a strong set of first-quarter numbers that could potentially...
Need a quote from a Motley Fool analyst? Alison Moore: Thank you, Georgia, and thanks, everyone, for joining. While it's been a short 8 weeks since our last call, we've accomplished a lot at Codexis.
Need a quote from a Motley Fool analyst? Alison Moore: Thank you, Georgia, and thanks, everyone, for joining. While it's been a short 8 weeks since our last call, we've accomplished a lot at Codexis.
Codexis, Inc. (CDXS) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDTCompany ParticipantsGeorgia Erbez - CFO & Chief Business OfficerAlison MooreBritton...
Presentation Operator MessageOperator Greetings, and welcome to the Codexis Report 2026 Q1 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my...
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Codexis (CDXS) beat Q1 estimates on revenue and EPS, reaffirmed full-year guidance, and highlighted its ECO Synthesis platform for RNA therapeutics, sparking after-market gains.
Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31,
REDWOOD CITY, Calif. — REDWOOD CITY, Calif. — Codexis Inc. on Thursday reported a loss of $8.7 million in its first quarter. On a per-share basis, the Redwood City, California-based company...
Codexis (NASDAQ:CDXS) affirms FY2026 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $74.234 million estimate.
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 60 percent increase over losses of $(0.25) per share from the same
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 1.67M | $2.72M | 0.00% | Added+4.0% | 2026-03-31 |
| DEShaw | quant | 979.8K | $1.60M | 0.00% | Added+56.0% | 2026-03-31 |
| FidelityFMR | fundamental | 412.6K | $672.53K | 0.00% | Trimmed-35.7% | 2026-03-31 |
| TwoSigma | quant | 242.0K | $394.39K | 0.00% | Added+507.9% | 2026-03-31 |
| RenTech | quant | 198.7K | $323.94K | 0.00% | Trimmed-73.1% | 2026-03-31 |
| TRowePrice | fundamental | 63.6K | $104 | 0.00% | Added+43.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.12 | — | — |
| 2026-05-07 | -0.14 | -0.10 | +26.83% |
| 2026-03-11 | -0.04 | 0.14 | +508.57% |
| 2025-11-06 | -0.13 | -0.22 | -73.68% |
| 2025-08-13 | -0.19 | -0.16 | +15.15% |
| 2025-05-14 | -0.21 | -0.25 | -20.48% |
| 2025-02-27 | -0.02 | -0.13 | -499.91% |
| 2024-10-31 | -0.21 | -0.29 | -35.51% |
| 2024-08-08 | -0.24 | -0.32 | -34.68% |
| 2024-05-02 | -0.14 | -0.16 | -17.07% |
| 2024-02-28 | -0.14 | -0.10 | +26.07% |
| 2023-11-02 | -0.26 | -0.31 | -18.79% |
| 2023-08-03 | -0.14 | -0.17 | -16.90% |
| 2023-05-04 | -0.25 | -0.34 | -36.76% |
| 2023-02-23 | -0.20 | -0.14 | +29.76% |
| 2022-11-03 | -0.16 | -0.15 | +4.54% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CDXS | +3.75% | +182.65% | +69.94% | +20.43% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.78% | +187.29% | +73.38% | +7.75% |